Zynerba Pharmaceuticals Achieves Target Enrollment in Exploratory …

– Top-line data from this study remains on track to report in September 2017 –

DEVON, Pa., June 08, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today announced that it has met its enrollment target of 16 patients in its Phase 2 FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in children with Fragile X syndrome (FXS). ZYN002 CBD gel is the first and only patent-protected, synthetic CBD that is formulated as a permeation-enhanced gel for transdermal delivery, and was awarded orphan drug designation by the U.S. Food and Drug Administration for the treatment for FXS.

Patients between the ages of 6 and 17 years

... read more at: http://www.nasdaq.com/press-release/zynerba-pharmaceuticals-achieves-target-enrollment-in-exploratory-phase-2-trial-of-zyn002-in-20170608-00333